Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK. Viswanadhapalli S, et al. Among authors: li x, li m. Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29. Mol Cancer Ther. 2019. PMID: 31142661 Free PMC article.
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
Tang W, Ramasamy K, Pillai SMA, Santhamma B, Konda S, Pitta Venkata P, Blankenship L, Liu J, Liu Z, Altwegg KA, Ebrahimi B, Pratap UP, Li X, Valente PT, Kost E, Sareddy GR, Vadlamudi RK, Nair HB, Tekmal RR, Viswanadhapalli S. Tang W, et al. Among authors: li x. Cell Death Discov. 2021 Aug 16;7(1):216. doi: 10.1038/s41420-021-00603-z. Cell Death Discov. 2021. PMID: 34400617 Free PMC article.
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Pratap UP, Sareddy GR, Liu Z, Venkata PP, Liu J, Tang W, Altwegg KA, Ebrahimi B, Li X, Tekmal RR, Viswanadhapalli S, McHardy S, Brenner AJ, Vadlamudi RK. Pratap UP, et al. Among authors: li x. Neurooncol Adv. 2021 Jul 17;3(1):vdab099. doi: 10.1093/noajnl/vdab099. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34485908 Free PMC article.
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Li M, Viswanadhapalli S, Santhamma B, Pratap UP, Luo Y, Liu J, Altwegg KA, Tang W, Liu Z, Li X, Ebrahimi B, Yan H, Zou Y, Konda S, Sareddy GR, Xu Z, Chen Y, Rao MK, Brenner AJ, Kaklamani VG, Tekmal RR, Ahmed G, Raj GV, Nickisch KJ, Nair HB, Vadlamudi RK. Li M, et al. Among authors: li x. Commun Biol. 2021 Oct 29;4(1):1235. doi: 10.1038/s42003-021-02741-7. Commun Biol. 2021. PMID: 34716410 Free PMC article.
SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z, Liu J, Ebrahimi B, Pratap UP, He Y, Altwegg KA, Tang W, Li X, Lai Z, Chen Y, Shen L, Sareddy GR, Viswanadhapalli S, Tekmal RR, Rao MK, Vadlamudi RK. Liu Z, et al. Among authors: li x. Breast Cancer Res. 2022 Apr 8;24(1):26. doi: 10.1186/s13058-022-01520-4. Breast Cancer Res. 2022. PMID: 35395812 Free PMC article.
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA, Viswanadhapalli S, Mann M, Chakravarty D, Krishnan S, Liu Z, Liu J, Pratap UP, Ebrahimi B, Sanchez JR, Li X, Ma S, Park BH, Santhamma B, Chen Y, Lai Z, Raj GV, Yuan Y, Zhou D, Sareddy GR, Tekmal RR, McHardy S, Huang TH, Rao MK, Vankayalapati H, Vadlamudi RK. Altwegg KA, et al. Among authors: li x. Cancer Res. 2022 Oct 17;82(20):3830-3844. doi: 10.1158/0008-5472.CAN-22-0698. Cancer Res. 2022. PMID: 35950923 Free PMC article.
182,275 results
You have reached the last available page of results. Please see the User Guide for more information.